🇺🇸 FDA
Pipeline program

[18F]PI-2620

IIBSP-FPI-2019-108

Phase 2 small_molecule active

Quick answer

[18F]PI-2620 for Down Syndrome, Alzheimer disease is a Phase 2 program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
The George Institute
Indication
Down Syndrome, Alzheimer disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials